iECURE, a Philadelphia, PA-based gene editing company, raised $65m in Series A-1 funding.
The round was led by Novo Holdings A/S and LYFE Capital with participation from Versant Ventures and OrbiMed Advisors. As part of the Series A-1 financing, Ray Camahort, Ph.D., Partner at Novo Ventures and Derek Yuan, Ph.D., Managing Director at LYFE Capital will join iECURE’s Board of Directors. Additionally, Tal Zaks, M.D., Ph.D., has been appointed to iECURE’s board as OrbiMed’s new representative on the Board of Directors. Stephen Squinto, Ph.D., will continue to serve on the Board of Directors as an independent member.
Led by CEO Joseph Truitt, iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need.
The company intends to use the funds to execute all the tasks necessary to begin clinical development of what could be the mutation-agnostic in vivo gene insertion therapeutic program. The funding is expected to enable completion of pre-IND activities, clinical trial initiation, and receipt of clinical data from the Phase 1/2 clinical trial of iECURE’s lead investigational product for Ornithine Transcarbamylase (OTC) deficiency as well as pre-IND activities for Citrullinemia Type 1 (CTLN1).
This financing, coupled with the $50m raised in the prior Series A financing announced in September 2021, will bring the company’s total funds raised to $115m.
FinSMEs
30/11/2022